Nasdaq-listed Therapix Biosciences Ltd., a Tel Aviv-based company developing a cannabinoid -based drug for the treatment of Tourette Syndrome, announced on Monday it had successfully completed a phase IIa clinical trial for its product. For daily updates, subscribe to our newsletter by clicking here. Read More
The post An Israeli Company Wants to Treat Tourette Syndrome With Cannabis appeared first on Dagga Magazine.